PH12021550621A1 - Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness - Google Patents

Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness

Info

Publication number
PH12021550621A1
PH12021550621A1 PH12021550621A PH12021550621A PH12021550621A1 PH 12021550621 A1 PH12021550621 A1 PH 12021550621A1 PH 12021550621 A PH12021550621 A PH 12021550621A PH 12021550621 A PH12021550621 A PH 12021550621A PH 12021550621 A1 PH12021550621 A1 PH 12021550621A1
Authority
PH
Philippines
Prior art keywords
treatment
dryness
symptoms
surface damage
ocular surface
Prior art date
Application number
PH12021550621A
Other languages
English (en)
Inventor
Markus Beier
Daniela Willen
Sonja Kr™Sser
Thomas SchlšTer
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of PH12021550621A1 publication Critical patent/PH12021550621A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12021550621A 2018-09-22 2021-03-18 Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness PH12021550621A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18196126 2018-09-22
EP18198440 2018-10-03
EP18202041 2018-10-23
PCT/EP2019/075406 WO2020058504A1 (en) 2018-09-22 2019-09-20 Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness

Publications (1)

Publication Number Publication Date
PH12021550621A1 true PH12021550621A1 (en) 2022-02-14

Family

ID=68240699

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550621A PH12021550621A1 (en) 2018-09-22 2021-03-18 Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness

Country Status (11)

Country Link
US (1) US20210346313A1 (zh)
EP (1) EP3852734A1 (zh)
JP (1) JP2022500461A (zh)
KR (1) KR20210080388A (zh)
CN (1) CN112739335A (zh)
AU (1) AU2019342426A1 (zh)
CA (1) CA3111873A1 (zh)
IL (1) IL281516A (zh)
PH (1) PH12021550621A1 (zh)
SG (1) SG11202102818YA (zh)
WO (1) WO2020058504A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017329772B2 (en) 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CA3091308A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
CN106511322B (zh) 2012-09-12 2021-09-17 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
PL3355990T3 (pl) * 2015-09-30 2019-11-29 Novaliq Gmbh Semifluorowane związki oraz ich kompozycje
AU2017329772B2 (en) * 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
WO2019068763A1 (en) * 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8

Also Published As

Publication number Publication date
WO2020058504A1 (en) 2020-03-26
JP2022500461A (ja) 2022-01-04
AU2019342426A1 (en) 2021-05-20
US20210346313A1 (en) 2021-11-11
EP3852734A1 (en) 2021-07-28
IL281516A (en) 2021-04-29
CA3111873A1 (en) 2020-03-26
KR20210080388A (ko) 2021-06-30
SG11202102818YA (en) 2021-04-29
CN112739335A (zh) 2021-04-30

Similar Documents

Publication Publication Date Title
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
EP4248971A3 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
MY186271A (en) Ophthalmic compositions and methods of use therefor
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
PH12021550620A1 (en) Ophthalmic composition for treatment of dry eye disease
NZ746468A (en) Methods of treating ocular conditions
EA202092748A1 (ru) Модуляторы экспрессии apol1
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
IL284344A (en) Pharmaceutical preparations for the eyes and methods for the treatment of diseases of the surface of the eye
PH12021550122A1 (en) Solubilized apyrases, methods and use
EA202091655A1 (ru) Композиции и способы лечения нарушений сетчатки
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
EP3691654A4 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
PH12018502704A1 (en) Treatment of retinal vascular disease using progenitor cells
EP3813794A4 (en) OPHTHALMIC COMPOSITIONS AND METHODS OF TREATING EYE DISORDERS
WO2017129577A8 (en) Ophthalmic gabapentin for the treatment of corneal ulcers
TW201613596A (en) Ophthalmic suspension preparation
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
EP3541323A4 (en) SCLERAL PROSTHESIS WITH A JAGGERED OR OTHER SURFACE FOR RETENTION IN THE SCLERAL TISSUE FOR THE TREATMENT OF PRESBYOPIA